Analyst Price Target is $36.20
▲ +139.26% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Mineralys Therapeutics in the last 3 months. The average price target is $36.20, with a high forecast of $45.00 and a low forecast of $27.00. The average price target represents a 139.26% upside from the last price of $15.13.
Current Consensus is
The current consensus among 6 contributing investment analysts is to buy stock in Mineralys Therapeutics.